MedReleaf Prescriber Program
To receive details of the MedReleaf Prescriber Program and updates on clinical information, please fill out the form below to register your interest.
Doctors
"*" indicates required fields
Important Resources
Links to the TGA – SAS Online and also individual State & Territory information can be found here.
Note that medical cannabis products are unregistered medicinal products
States & Territory Information:
About the Special Access Scheme and Authorised Prescriber Scheme
Access pathways available for medicinal cannabis
There are four pathways for accessing ‘unapproved’ medicinal cannabis products:
Pathway 1
Authorised Prescriber - Established History of Use
Medical practitioners can apply to become Authorised Prescribers of specified medicinal cannabis products without the need for approval from a Human Research Ethics Committee or endorsement from a specialist college.
Medicinal cannabis products and indications deemed by the TGA to have an established history of use are specified below, in the List of medicines with established history of use:
Pathway 2
Authorised Prescriber - Standard
Medical practitioners can apply to become Authorised Prescribers of medicinal cannabis products not included in the List of medicines with established history of use via the standard pathway.
This pathway requires approval from a Human Research Ethics Committee or endorsement from a specialist college before applying to the TGA.
Pathway 3
SAS Category A notification
Category A is a notification pathway that may be accessed by a prescribing medical practitioner or by a health practitioner on behalf of a prescribing medical practitioner.
Category A patients are defined as being seriously ill if they have a condition from which death is reasonably likely to occur within a matter of months or from which premature death is reasonably likely to occur in the absence of early treatment.
Pathway 4
SAS Category B application
The SAS Category B pathway is an application pathway available to prescribing healthcare practitioners, including Medical Practitioners and Nurse Practitioners. When applying to access an unapproved medicinal cannabis product on behalf of a patient under the SAS Category B pathway, prescribers must provide a clinical justification. The justification should include the seriousness of the patient’s condition, consideration for the use of medicines that are included in the ARTG and the potential risks and benefits of using the proposed unapproved medicine.
There are no restrictions on the medical conditions for which a prescriber may apply via the SAS to access an unapproved medicinal cannabis product for their patient, provided the prescriber has the appropriate knowledge on the condition being treated and on the medicinal cannabis product they wish to prescribe.
Key features of SAS and AP pathways
| Pathway | Authorised Prescriber – Established history of use | Authorised Prescriber – standard | SAS Category A notification | SAS Category B application |
|---|---|---|---|---|
| Medical practitioners can apply | Yes | Yes | Yes | Yes |
| Other health practitioners can apply | No | No | No | Yes |
| Specified list of medicines | Yes | No | No | No |
| Requires approval from a HREC | No | Yes | No | No |
| Requires submission to TGA for every patient | No | No | Yes | Yes |
| Requires six monthly patient reports | Yes | Yes | No | No |
The MedReleaf Concession Scheme (MCS)
To provide easier access for Australians* to our plant-based medicines, MedReleaf Australia os proud to offer patient concession scheme for doctors to prescribe to qualified patients.
*The MedReleaf Concession Scheme (MCS) is only available to the following cardholders†
- Pensioner Concession Card
- Commonwealth Seniors Health Card
- Health Care Card
- Veterans Card Holders (DVA)
† Note: Concession and health care card patients must have an active Centrelink Customer Reference Number (CRN). Cardholders only (not their dependents listed on the card) are entitled to the concession prices.
NB: Medicinal cannabis is an unregistered medicine only available on prescription from a medical practitioner via the TGA’s Special Access Scheme.